Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 8/20 | 0.71 |
| ▸ | SCN3A | Q9NY46 | 9/20 | 0.56 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.52 |
| ▸ | SCN1A | P35498 | 1/20 | 0.52 |
| ▸ | SCN4A | P35499 | 1/20 | 0.52 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.52 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.52 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.52 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.52 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | BTK | Q06187 | 1/20 | 0.48 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.47 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.47 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.47 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL310422 | 1.00 | KCNH2 (0.71) | KCNH2SCN3ASCN9ASCN1ASCN4A | |
| SCHEMBL22546665 | 1.00 | KCNH2 (0.71) | KCNH2SCN3ASCN9ASCN1ASCN4A | |
| SCHEMBL29388566 | 1.00 | KCNH2 (0.71) | KCNH2SCN3ASCN9ASCN1ASCN4A | |
| SCHEMBL840053 | 1.00 | KCNH2 (0.71) | KCNH2SCN3ASCN9ASCN1ASCN4A | |
| SCHEMBL29989600 | 1.00 | KCNH2 (0.71) | KCNH2SCN3ASCN9ASCN1ASCN4A | |
| SCHEMBL24491222 | 1.00 | KCNH2 (0.71) | KCNH2SCN3ASCN9ASCN1ASCN4A | |
| SCHEMBL1104532 | 0.90 | KCNH2 (0.59) | KCNH2SCN3ASCN9ASCN1ASCN4A | |
| SCHEMBL4712753 | 0.89 | KCNH2 (0.58) | KCNH2SCN3ASCN9ASCN1ASCN4A | |
| SCHEMBL12206746 | 0.89 | KCNH2 (0.58) | KCNH2SCN3ASCN9ASCN1ASCN4A | |
| SCHEMBL12973303 | 0.88 | KCNH2 (0.57) | KCNH2SCN3ASCN9ASCN1ASCN4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112153968-A | Process for the preparation of alpha-carboxamide pyrrolidine derivatives | 生物基因公司 | 2020-12-29 | — | — | CN | disclosed |
| EP-1934177-B1 | PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | GLAXO GROUP LTD (GB) | 2012-05-02 | — | — | EP | disclosed |
| US-8153681-B2 | Method of treating epilepsy by administering 5-(4{[(2-fluorophenyl)methyl]oxy}phenyl)prolinamide | Convergence Pharmaceuticals Limited (GB) | 2012-04-10 | — | — | US | disclosed |
| US-8153681-B2 | Method of treating epilepsy by administering 5-(4{[(2-fluorophenyl)methyl]oxy}phenyl)prolinamide | Convergence Pharmaceuticals Limited (GB) | 2012-04-10 | — | — | US | disclosed |
| US-8153681-B2 | Method of treating epilepsy by administering 5-(4{[(2-fluorophenyl)methyl]oxy}phenyl)prolinamide | Convergence Pharmaceuticals Limited (GB) | 2012-04-10 | — | — | US | disclosed |
| US-8143306-B2 | Methods of treating bipolar disorders | Convergence Pharmaceuticals Limited (GB) | 2012-03-27 | — | — | US | disclosed |
| US-8143306-B2 | Methods of treating bipolar disorders | Convergence Pharmaceuticals Limited (GB) | 2012-03-27 | — | — | US | disclosed |
| US-8143306-B2 | Methods of treating bipolar disorders | Convergence Pharmaceuticals Limited (GB) | 2012-03-27 | — | — | US | disclosed |
| US-20110098335-A1 | NOVEL COMPOUNDS | Convergence Pharmaceuticals Limited (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20110098335-A1 | NOVEL COMPOUNDS | Convergence Pharmaceuticals Limited (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20100105754-A1 | 5-(4PHENYL)PROLINAMIDE FOR TREATMENT OF EPILEPSY | GLAXO GROUP LIMITED (GB) | 2010-04-29 | — | — | US | disclosed |
| US-20100105754-A1 | 5-(4PHENYL)PROLINAMIDE FOR TREATMENT OF EPILEPSY | GLAXO GROUP LIMITED (GB) | 2010-04-29 | — | — | US | disclosed |
| US-7655693-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2010-02-02 | — | — | US | disclosed |
| US-7655693-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2010-02-02 | — | — | US | disclosed |
| US-20080306122-A1 | Novel Compounds | Convergence Pharmaceuticals Limited (GB) | 2008-12-11 | — | — | US | disclosed |
| US-20080306122-A1 | Novel Compounds | Convergence Pharmaceuticals Limited (GB) | 2008-12-11 | — | — | US | disclosed |
| US-20080280969-A1 | Novel Compounds | GLAXO GROUP LIMITED | 2008-11-13 | — | — | US | disclosed |
| US-20080280969-A1 | Novel Compounds | GLAXO GROUP LIMITED | 2008-11-13 | — | — | US | disclosed |
| WO-2007042239-A1 | PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | GLAXO GROUP LIMITED (GB) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007042250-A1 | PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | GLAXO GROUP LIMITED (GB) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098335-A1 | NOVEL COMPOUNDS | SCN1A, SCN1B, SCNN1B | KCNH2 65/4885SCN3A 8/4885SCN9A 35/4885 |
| US-20080306122-A1 | Novel Compounds | CYP11B1, CYP11B2, CYP46A1 | KCNH2 3313/4885SCN3A 2352/4885SCN9A 1641/4885 |
| US-20080280969-A1 | Novel Compounds | CYP11B2, CYP46A1, SLC10A1 | KCNH2 1998/4885SCN3A 2634/4885SCN9A 1889/4885 |
| US-20100105754-A1 | 5-(4PHENYL)PROLINAMIDE FOR TREATMENT OF EPILEPSY | SCN5A, SCN1A, SCN7A | KCNH2 58/4885SCN3A 6/4885SCN9A 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.